| Home | Log In | Register | Our Services | My Account | Contact | Help |
Sphere Medical (SPHR)
Ruthbaby
- 06 May 2012 08:06
The Wales Life Sciences Investment Fund 25,000,000 17.64%
Woodford Patient Capital Trust Plc 23,125,000 16.31%
LSP Life Sciences Fund 10,904,000 7.69%
Ortho-Clinical Diagnostics 8,141,250 5.74%
Fidelity Worldwide Investments 6,264,649 4.42%
Octopus Investments 6,250,000 4.41%
Ruffer LLP 5,653,895 3.99%
Royal London Asset Management 5,624,185 3.97%
Herald Investment Management 4,711,965 3.32%
Should be an exciting year ahead with developments.
Anybody had a look at this company?
Ruthbaby
- 02 May 2017 22:03
- 64 of 71
This is very good news...
CC
- 03 May 2017 20:20
- 65 of 71
For the first time we now have evidence the product will sell in a commercial way. Orders from 6 hospitals in the last 4 months.
They are going to need more cash in the next 6 months, possibly sooner. Whether that comes from their existing lender SVB or shareholders or a combination of both remains to be seen.
I suggest the balance between sales growth and therefore reduction in cash burn vs funding required is finely balanced. If they can get to 10 orders by June then I think all concerns over future funding will disappear.
Ruthbaby
- 04 May 2017 19:39
- 66 of 71
I will most certainly be adding to my holding if another open offer comes round...which is not 100% certain yet.
I believe that most forecasts on potential sales has never included pediatric customers.
Very strange as they are the ones at most risk from hospital anemia... Manchester is a big contract win. There network in the North Western area is very respected. I expect other orders to flow from this validation alone. Italy now open and doing business and Spain about to launch this week. The technology is fantastic. Remember all these units going out to customers will build up the data base for applying for USA license in a year or so....I think this is where SVB are looking....hence the £3 million loan...
Great contact profile....
Ruthbaby
- 06 Jun 2017 11:31
- 67 of 71
Sphere Medical Holding plc
Commercialisation Update
~ Proxima building European sales traction in adult and paediatrics ~
Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, today provides a commercialisation update for its wholly-owned Proxima platform product.
Proxima 4 was launched into the European market in December 2016 and a positive reaction to the product has been received with forward visibility of an expanding sales pipeline. Over 40 hospital departments have engaged with Sphere Medical on Proxima 4 and have requested evaluations, of which more than 30 have undergone a product demonstration. Evaluations, in which the system is connected to patients, have been conducted at 14 hospital departments and to date six hospital departments across three countries have placed orders for Proxima 4, more than doubling the key metrics over the two months from the announcement of our Full Year Results on 28 February 2017. Follow-up discussions are underway with the other hospitals which have conducted evaluations.
One of the advantages of Proxima 4 over the previously available product, Proxima 3, is the paediatric application, where a patient's blood conservation during procedures is typically even more critical than in adults. Since the launch of Proxima 4, the system has been connected to children for the first time and the Royal Manchester Children's Hospital has already placed an order, becoming the first paediatric unit to purchase Proxima product.
In continental Europe, the list of product distributors continues to expand and now includes Eumedics Medizintechnik GmbH in Austria. Training, marketing and monitoring of patients in hospitals are now underway via Burke and Burke in Italy and Prhoinsa is on track to commence marketing in Spain imminently.
Production processes have now been fully converted to Proxima 4 from the earlier product iteration, Proxima 3, and the establishment of Sphere's manufacturing facility in Wales has continued to progress according to plan. As is normal in the ramp up of wafer based technologies, a key focus remains on increasing product yield. We have been experiencing occasional limitations on the supply of Proxima 4 sensors. However, whilst supply is currently low, the Board is confident that yields will improve and there will be sufficient supply in place to meet the sales targets for the current full year and beyond.
Commenting on the commercial traction of Proxima, Wolfgang Rencken, CEO of Sphere Medical, said: "We are very pleased with the market reaction to Proxima 4 and encouraged by the early response from customers. We look forward to building on this through 2017."
Bullshare
- 29 Jun 2017 11:38
- 68 of 71
Come and celebrate 6 years of investor evenings with Shares on July 11 and receive a Shares goody bag worth over £150!.
We can’t believe that 6 years have passed since we started our investor evenings, in that time many 1000’s of private investors, fund managers, brokers and analysts have come along and heard from 100’s of listed companies present their investment opportunity.
To celebrate our next investor evening on 11 July in London, we will give all attendees a free goody bag containing:
1) a one year subscription to Shares magazine digital. Each week you will receive the latest Shares digital weekly magazine where our team of experts will give you a multitude of investment ideas. You will also gain access to the Shares investor toolkit with live news, LIVE share prices, portfolio and research tools (value £120)
2) a bottle of champagne (value £20)
3) The DIY Investor book written by Andy Bell, CEO of AJ Bell (RRP £17.99)
On the evening hear from:
MetalNRG (NEX.MNRG) - MetalNRG is an NEX Exchange quoted natural resource investing company seeking investments in precious and strategic metals. Metal NRG is reviewing opportunities in various commodities and jurisdictions and anticipates updating the market shortly with regard to its initial target investments. It recently announced its first investing step with the creation of the Palomino Cobalt Project in Western Australia. MetalNRG’s CEO, the well-known resources entrepreneur Paul Johnson (ex-CEO of Metal Tiger), will provide an update on the company’s investment strategy.
Midatech Pharma (MTPH) - Midatech has a balanced portfolio of fast-growth marketed oncology products and development programmes for its own products, using its proprietary platform technologies to target diseases with unmet medical need. Midatech offers the potential for rapid revenue growth through its differentiated product portfolio and exciting development pipeline, supported by strong IP and, an ambitious and highly experienced leadership team.
Sphere Medical (SPHR) - Sphere Medical’s vision is to become a leading solution provider to the critical care market offering innovative, frequent on demand, point of care diagnostic and monitoring products to enable closer control of therapeutic response, improve patient outcomes and reduce the overall cost of care. The Company’s strategy is focused on the Proxima platform for measuring blood gases, electrolytes and metabolites. The latest generation of the product, Proxima 4, was launched in December 2016 and is being marketed directly to the critical care market in the UK, Germany, The Netherlands and Belgium, and by distributors in Italy and Spain.
Xpediator - Xpediator Plc is expected to IPO on the London Stock Exchange’s AIM market in July 2017. It is a well-established international provider of freight management services operating across the UK and Europe with a particular focus on, and expertise in, the CEE markets. The Group currently employs over 600 people with its operational headquarters in Braintree, England, and country offices in Bulgaria, Lithuania, Estonia, Macedonia, Montenegro, Moldova, Romania and Serbia operating from 22 sites in total.
Places at this event are very limited, so register now for your free ticket.
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Tuesday 11 July 2017
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Paul Johnson, CEO - Metal NRG (MNRG) • Dr Jim Phillips, CEO - Midatech Pharma (MTPH) • Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR) • Stephen Blyth, CEO - Xpediator + More to be announced | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | Metal NRG is an NEX Exchange quoted natural resource investing company seeking investments in precious and strategic metals. Metal NRG is reviewing opportunities in various commodities and jurisdictions and anticipates updating the market shortly with regard to its initial target investments.
|
 | Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. It is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of diabetes, cancer and neuroscience/ophthalmology. Midatech’s strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies. |
 | Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs. |
 | Xpediator is the holding company for the Group, a well-established international provider of freight management services operating across the UK and Europe with a particular focus on, and expertise in, the CEE markets. he Group currently employs over 600 people with its operational headquarters in Braintree, England, and country offices in Bulgaria, Lithuania, Estonia, Macedonia, Montenegro, Moldova, Romania and Serbia operating from 22 sites in total. The Group has three main business areas which are managed autonomously on a day-to-day basis but directed centrally to cross-sell services to the Group’s customer base: - Freight forwarding, trading under the Delamode brand. - Logistics and warehousing, trading under the Delamode brand and EMT; and pallet distribution services, trading under the Pall-Ex brand. - Transport services, trading under the Affinity brand.
|
Ruthbaby
- 30 Jun 2017 12:06
- 69 of 71
10:19 30 Jun 2017
Wolfgang Rencken, chief executive of Sphere Medical Holding PLC (LON:SPHR) tells Proactive he's hugely excited their Proxima 4 critical care blood gas monitoring system can now work with electronics giant Philips' IntelliVue Patient Monitoring Systems.
The combination with Philips’ equipment means that Proxima's results can be recorded and displayed alongside other critical monitoring information, such as blood pressure, ECG, EEG, respiratory rate, cardiac output and temperature.
http://tinyurl.com/yafff2gm
Ruthbaby
- 10 Jul 2017 20:18
- 70 of 71
hangon - 07 Sep 2017 15:02 - 71 of 71
Yet records since 2012 show sp has declined from ~£1 (DYOR) to c.1p today. That is a massive loss by any imagination and Directors should be held to account over what they propose doing to restore the money entrusted to them by investors, who relied on the Company's outpourings of "Prospects" - which includes each and every Director, if I'm not mistaken ( Otherwise, what useful function are they performing?)....DYOR.
RNS:- What I read today( Sept 2017)- suggests Sphere Medical are cancelling their AIM-listing and going private....
well let's hope the good-ship has enough lifeboats.
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter